<DOC>
	<DOC>NCT01452763</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy of TAK-438, once daily (QD) compared to AG-1749 (Lansoprazole) in patients with a history of gastric or duodenal ulcer who require long-term therapy of low-dose aspirin.</brief_summary>
	<brief_title>Efficacy and Safety of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Low-dose Aspirin</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Duodenal Ulcer</mesh_term>
	<mesh_term>Stomach Ulcer</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Lansoprazole</mesh_term>
	<mesh_term>Dexlansoprazole</mesh_term>
	<criteria>1. Participants who require continuous lowdose aspirin therapy during the treatment period with the study drug 2. Participants who have a history of ulcer in stomach or duodenum, endoscopically confirmed 3. Outpatient (including inpatient for examinations) 1. Participants scheduled to change the type and dosage regimen of lowdose aspirin 2. Participants with ulcers or bleeding in stomach or duodenum, endoscopically confirmed 3. Participants with small intestine bleeding, large intestine bleeding, or gastrointestinal bleeding of unknown etiology 4. Participants who have a history of surgery which affects gastric acid secretion (e.g., resection of upper gastrointestinal tract, vagotomy) or who are scheduled to undergo such surgery 5. Participants with a previous or current history of ZollingerEllison syndrome, or other gastric acid hypersecretion disorders 6. Participants with a previous or current history of aspirininduced asthma</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>